%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 14 0 R ] /Count 2 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R /F4 11 0 R >> /ExtGState << /GS1 12 0 R /GS2 13 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260402121639+00'00') /ModDate (D:20260402121639+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Contents 7 0 R >> endobj 7 0 obj << /Length 6178 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Therapeutics Announces The Closing of a $91)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(Million Series B Financing)] TJ ET BT 35.000 734.017 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 692.827 Td /F4 12.0 Tf [(Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the)] TJ ET BT 35.000 678.175 Td /F4 12.0 Tf [(preclinical development of the Biologics and Cell Therapy platform, as well as general corporate)] TJ ET BT 35.000 663.523 Td /F4 12.0 Tf [(purposes)] TJ ET BT 35.000 636.871 Td /F4 12.0 Tf [(Financing led by Sino Biopharmaceutical Limited and 3W Fund and includes other healthcare focused)] TJ ET BT 35.000 622.219 Td /F4 12.0 Tf [(funds)] TJ ET BT 35.000 595.567 Td /F1 12.0 Tf [(New York and Hong Kong ?? November 18th, 2021 ?? Treadwell Therapeutics, a clinical-stage)] TJ ET BT 35.000 580.915 Td /F1 12.0 Tf [(biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, today)] TJ ET BT 35.000 566.263 Td /F1 12.0 Tf [(announced the closing of an oversubscribed Series B financing, which raised more than $91 million.)] TJ ET BT 35.000 551.611 Td /F1 12.0 Tf [(The financing was led by Sino Biopharmaceutical Limited and 3W Fund Management Limited \(??3W)] TJ ET BT 35.000 536.959 Td /F1 12.0 Tf [(Fund?)] TJ ET BT 75.692 536.959 Td /F1 12.0 Tf [()] TJ ET BT 79.028 536.959 Td /F1 12.0 Tf [(\), and included new investors including renowned culture entrepreneur and investor Mr. Adrian)] TJ ET BT 35.000 522.307 Td /F1 12.0 Tf [(Cheng, Prosperous Alliance, Alpha Win Capital, Fortune Ocean Growth Fund L.P. and, along with)] TJ ET BT 35.000 507.655 Td /F1 12.0 Tf [(existing investors TIO Bioventures, and other undisclosed institutional and individual investors.)] TJ ET BT 35.000 481.003 Td /F1 12.0 Tf [(??Our team is very excited to announce the closing of this transformative Series B financing, and are)] TJ ET BT 35.000 466.351 Td /F1 12.0 Tf [(very grateful to our investors, both old and new, for their belief, commitment and support of our goal to)] TJ ET BT 35.000 451.699 Td /F1 12.0 Tf [(build a globally impactful Biotechnology organization,?)] TJ ET BT 329.804 451.699 Td /F1 12.0 Tf [()] TJ ET BT 333.140 451.699 Td /F1 12.0 Tf [( said Shane Burgess, Chairman and co-CEO of)] TJ ET BT 35.000 437.047 Td /F1 12.0 Tf [(Treadwell Therapeutics. ??Since our company was founded in July 2019, we have made significant)] TJ ET BT 35.000 422.395 Td /F1 12.0 Tf [(strides in building and validating our clinical stage small molecule portfolio, as well as broadening our)] TJ ET BT 35.000 407.743 Td /F1 12.0 Tf [(pre-clinical pipeline of novel biologic and cell therapy assets. The funding will allow us to further the)] TJ ET BT 35.000 393.091 Td /F1 12.0 Tf [(development of our product candidates, as well as to continue building out our organization in all)] TJ ET BT 35.000 378.439 Td /F1 12.0 Tf [(functions with the talent necessary to support our mission, which is to translate novel scientific insights)] TJ ET BT 35.000 363.787 Td /F1 12.0 Tf [(into hope for patients in need,?)] TJ ET BT 206.444 363.787 Td /F1 12.0 Tf [()] TJ ET BT 209.780 363.787 Td /F1 12.0 Tf [( added Dr. Michael Tusche, co-CEO of Treadwell Therapeutics.)] TJ ET BT 35.000 337.135 Td /F1 12.0 Tf [(??Treadwell Therapeutics is a company steeped in world class science and has an exciting pipeline of)] TJ ET BT 35.000 322.483 Td /F1 12.0 Tf [(first in class drugs with compelling signs of clinical activity,?)] TJ ET BT 357.092 322.483 Td /F1 12.0 Tf [()] TJ ET BT 360.428 322.483 Td /F1 12.0 Tf [( said Dr. Mao Li, Chief Medical Officer at)] TJ ET BT 35.000 307.831 Td /F1 12.0 Tf [(Sino Biopharmaceutical Limited. ??We are excited to be part of Treadwell in the next phase of its)] TJ ET BT 35.000 293.179 Td /F1 12.0 Tf [(growth.?)] TJ ET BT 87.692 293.179 Td /F1 12.0 Tf [()] TJ ET BT 35.000 266.527 Td /F1 12.0 Tf [(??We are excited to support Treadwell to further develop its strong pipeline of first in class drugs to)] TJ ET BT 35.000 251.875 Td /F1 12.0 Tf [(help patients worldwide.?)] TJ ET BT 176.396 251.875 Td /F1 12.0 Tf [()] TJ ET BT 179.732 251.875 Td /F1 12.0 Tf [( said Cathy Chen of 3W Fund. ??We look forward to significant growth of)] TJ ET BT 35.000 237.223 Td /F1 12.0 Tf [(Treadwell in the near future.?)] TJ ET BT 197.744 237.223 Td /F1 12.0 Tf [()] TJ ET BT 35.000 210.571 Td /F1 12.0 Tf [(The proceeds from this financing will allow Treadwell to continue the clinical and pre-clinical)] TJ ET BT 35.000 195.919 Td /F1 12.0 Tf [(development of its broad, multi-modality pipeline. This includes the company sponsored TWT-101 study)] TJ ET BT 35.000 181.267 Td /F1 12.0 Tf [(of CFI-402411 in advanced solid tumors as a monotherapy and in combination with pembrolizumab; the)] TJ ET BT 35.000 166.615 Td /F1 12.0 Tf [(company sponsored TWT-202 study of CFI-400945 in leukemia as a monotherapy and in combination)] TJ ET BT 35.000 151.963 Td /F1 12.0 Tf [(with decitabine or azacitidine, an IND filing in late 2021 and subsequent company sponsored study of)] TJ ET BT 35.000 137.311 Td /F1 12.0 Tf [(CFI-402257 in metastatic ER+ Breast cancer, as well as other opportunistic trials. The Series B)] TJ ET BT 35.000 122.659 Td /F1 12.0 Tf [(financing will also support Treadwell??s continued development and validation of its preclinical)] TJ ET BT 35.000 108.007 Td /F1 12.0 Tf [(pipeline of novel biologic and cell therapy approaches, the latter of which is expected to enter the clinic)] TJ ET BT 35.000 93.355 Td /F1 12.0 Tf [(around early 2023. Lastly, the funding will allow Treadwell to continue to grow and operationalize the)] TJ ET q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /Font /Subtype /Type1 /Name /F4 /BaseFont /Helvetica-Oblique /Encoding /WinAnsiEncoding >> endobj 12 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 13 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 14 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 16 0 R 18 0 R ] /Contents 15 0 R >> endobj 15 0 obj << /Length 2607 >> stream 0.000 0.000 0.000 rg BT 35.000 820.168 Td /F1 12.0 Tf [(organization with world class talent and infrastructure.)] TJ ET BT 35.000 789.484 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET BT 35.000 760.294 Td /F1 12.0 Tf [(Treadwell Therapeutics is a science driven, clinical-stage, multi-modality oncology company, spun out)] TJ ET BT 35.000 745.642 Td /F1 12.0 Tf [(of the University Health Network \(UHN\), in Toronto, Canada. The company is developing first-in-class)] TJ ET BT 35.000 730.990 Td /F1 12.0 Tf [(and best-in-class medicines to address unmet needs in patients with cancer. Founded by a cadre of)] TJ ET BT 35.000 716.338 Td /F1 12.0 Tf [(pre-eminent scientific luminaries, including Dr. Tak W. Mak, the Company??s robust, internally)] TJ ET BT 35.000 701.686 Td /F1 12.0 Tf [(developed clinical stage pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a best-)] TJ ET BT 35.000 687.034 Td /F1 12.0 Tf [(in-class TTK inhibitor, CFI-402257, and CFI-402411, an oral immunomodulatory kinase inhibitor with)] TJ ET BT 35.000 672.382 Td /F1 12.0 Tf [(activity toward HPK1. Treadwell also has a robust pre-clinical pipeline with multiple biologic and next)] TJ ET BT 35.000 657.730 Td /F1 12.0 Tf [(generation TCR based autologous cell therapy programs. For more information, please visit)] TJ ET BT 35.000 643.078 Td /F1 12.0 Tf [(www.treadwelltx.com.)] TJ ET BT 35.000 612.393 Td /F3 14.0 Tf [(Contact)] TJ ET BT 35.000 583.203 Td /F1 12.0 Tf [(Investors:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 580.593 m 87.020 580.593 l S 0.000 0.000 0.800 rg BT 35.000 568.551 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 565.941 m 137.192 565.941 l S 0.000 0.000 0.000 rg BT 35.000 541.899 Td /F1 12.0 Tf [(General inquiries:)] TJ ET 0.000 0.000 0.000 RG 35.000 539.289 m 129.032 539.289 l S 0.000 0.000 0.800 rg BT 35.000 527.247 Td /F1 12.0 Tf [(info@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 524.637 m 149.876 524.637 l S 0.000 0.000 0.000 rg BT 35.000 500.595 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 485.943 Td /F1 12.0 Tf [(November 18, 2021)] TJ ET q 35.000 483.012 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 16 0 obj << /Type /Annot /Subtype /Link /F 28 /A 17 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 566.2197 137.1920 578.4297 ] >> endobj 17 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj 18 0 obj << /Type /Annot /Subtype /Link /F 28 /A 19 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 524.9157 149.8760 537.1257 ] >> endobj 19 0 obj << /Type /Action /S /URI /URI (mailto:info@treadwelltx.com) >> endobj xref 0 20 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000355 00000 n 0000000384 00000 n 0000000533 00000 n 0000000636 00000 n 0000006866 00000 n 0000006973 00000 n 0000007082 00000 n 0000007195 00000 n 0000007311 00000 n 0000007368 00000 n 0000007425 00000 n 0000007556 00000 n 0000010216 00000 n 0000010349 00000 n 0000010426 00000 n 0000010559 00000 n trailer << /Size 20 /Root 1 0 R /Info 5 0 R /ID[<0726925090fb8b6725490c21d4e72db9><0726925090fb8b6725490c21d4e72db9>] >> startxref 10638 %%EOF